Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

9.78
+0.57006.19%
Post-market: 9.780.00000.00%19:30 EDT
Volume:1.76M
Turnover:17.03M
Market Cap:1.65B
PE:-5.76
High:9.86
Open:9.31
Low:9.31
Close:9.21
52wk High:11.66
52wk Low:4.35
Shares:168.65M
Float Shares:130.00M
Volume Ratio:1.24
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6972
EPS(LYR):-3.1619
ROE:-26.08%
ROA:-14.51%
PB:1.68
PE(LYR):-3.09

Loading ...

Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?

Simply Wall St.
·
Jun 18

Vir Biotechnology Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jun 11

Vir Biotechnology Inc : Morgan Stanley Raises Target Price to $27.00 From $23.00

THOMSON REUTERS
·
Jun 11

Vir Biotechnology names Timothy Coughlin to board, taps him as audit committee chair

Reuters
·
Jun 11

Vir Biotechnology Announces Appointment of Timothy Coughlin to Its Board of Directors

THOMSON REUTERS
·
Jun 11

Vir Biotechnology Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 03

Vir director Janet Napolitano disposes of 3,200 Vir Biotechnology shares for $30,240

Reuters
·
Jun 03

Vir Biotechnology SVP, Chief Accounting Officer Brent Sabatini sells 379 shares for $3,581.55

Reuters
·
Jun 03

H.C. Wainwright Sticks to Their Buy Rating for Vir Biotechnology (VIR)

TIPRANKS
·
May 28

Vir Biotechnology shareholders elect three directors at annual meeting

Reuters
·
May 28

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR)

TIPRANKS
·
May 27

Assessing Vir Biotechnology (VIR) Valuation After Hepatitis Delta Data Update And Astellas Oncology Partnership

Simply Wall St.
·
May 25

Brii Biosciences says arbitration with Vir clouds elebsiran hepatitis B program future

Reuters
·
May 22

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)

TIPRANKS
·
May 20

BRIEF-Vir Biotechnology To Present Complete Week 96 Data From Mid Stage Solstice Clinical Trial

Reuters
·
May 19

Vir to present Phase 2 SOLSTICE Week 96 hepatitis delta data at EASL 2026

Reuters
·
May 19

Vir Biotechnology to Present Complete Week 96 Data From Phase 2 Solstice Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (Easl) Congress 2026

THOMSON REUTERS
·
May 19

Vir Biotechnology (VIR) Gets a Buy from Bank of America Securities

TIPRANKS
·
May 07

Vir Biotechnology Q1 EPS USD -0.85

Reuters
·
May 07

Vir Biotechnology Q1 net loss widens

Reuters
·
May 07